Announced Tue, 4 Nov · 21:05 IST

Nuvama Wealth Management Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Nov-2025.

Stock SplitCorporate Actions View source PDF

NUVAMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Nuvama Wealth Management's board, at its meeting on November 4, 2025, approved unaudited consolidated and standalone financial results for Q2 and H1 FY26 (ended September 30, 2025) alongside three key corporate actions. The board declared an interim dividend of Rs. 70 per equity share (on face value of Rs. 10), with the record date fixed as November 11, 2025 and payout on or before December 3, 2025. The board also approved a sub-division/split of equity shares in a 1:5 ratio (one Rs. 10 share to become five Rs. 2 shares), subject to shareholder approval via postal ballot, aimed at improving affordability and liquidity for retail investors. Additionally, Rs. 200 crore was approved for subscribing to the rights issue of wholly-owned subsidiary Nuvama Wealth Finance Limited at Rs. 800 per share (Rs. 10 face value plus Rs. 790 premium). On a standalone basis, Q2 FY26 net profit fell to Rs. 46.35 crore from Rs. 316.84 crore in Q2 FY25, largely because last year's quarter included a one-time Rs. 256.83 crore dividend from subsidiaries, while H1 FY26 standalone PAT stood at Rs. 267.83 crore versus Rs. 363.38 crore in H1 FY25.

Likely market impact

The 1:5 stock split is expected to lower the per-share price, making the stock more accessible to retail investors and boosting trading liquidity, while the Rs. 70 interim dividend rewards shareholders with healthy cash returns. The lower headline Q2 profit reflects timing of subsidiary dividends rather than core business weakness, though investors should note that the stock split and postal ballot process remain subject to shareholder and regulatory approvals.